跳至主要内容
临床试验/NCT01410747
NCT01410747已完成不适用

Specified Drug Use-Results Survey on Long-Term Treatment for Prograf® Capsules 0.5 mg, 1 mg Lupus Nephritis

Astellas Pharma Inc0 个研究点目标入组 1,484 人开始时间: 2007年4月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1,484
主要终点
Incidence of renal events (renal failure and progression to dialysis)

研究概览

简要总结

To evaluate the safety and efficacy of tacrolimus for lupus nephritis under actual-use.

详细描述

The objectives of the survey are to evaluate the safety and efficacy of tacrolimus for lupus nephritis under actual-use situations, and to identify factors that might affect the safety and efficacy of tacrolimus. In addition, long-term renal outcome will be evaluated.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

tacrolimus group

Oral

干预措施: Tacrolimus (Drug)

结局指标

主要结局

Incidence of renal events (renal failure and progression to dialysis)

时间窗: Up to 10 years

次要结局

  • 24-hour urinary protein(Baseline, 4 week, 8 week, 12 week, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year, 9 year, 10 year)
  • Urinary red blood cell (RBC) count(Baseline, 4 week, 8 week, 12 week, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year, 9 year, 10 year)
  • Serum creatinine(Baseline, 4 week, 8 week, 12 week, 1 year, 2 year, 3 year, 4 year, 5 year, 6 year, 7 year, 8 year, 9 year, 10 year)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验